Chervinsky P
Allergy Associates, Inc., New England Research Center, North Dartmouth, Massachusetts, USA.
Clin Ther. 1996 Sep-Oct;18(5):790-6; discussion 789. doi: 10.1016/s0149-2918(96)80039-7.
A new double-strength (84 micrograms/spray) formulation of beclomethasone dipropionate (BDP-ds) as an aqueous suspension has been introduced to control symptoms of allergic rhinitis with once-daily intranasal dosing. This paper reviews the results of three clinical reports which show that BDP-ds given once a day is more effective than placebo and as effective as regular-strength beclomethasone dipropionate given twice daily in reducing the nasal symptoms of seasonal allergic rhinitis. Symptom improvement was seen within 2 days of treatment initiation and was maintained for the subsequent 4 weeks. BDP-ds was found to be as safe and well tolerated as placebo. Adverse effects, which were generally mild, included headache, nasal burning/irritation, epistaxis, coughing, and pharyngitis. BDP-ds is safe for children as young as 6 years of age, and its once-daily dosing schedule may improve patient compliance.
一种新的双强度（84微克/喷）二丙酸倍氯米松（BDP-ds）水性混悬液制剂已被引入，用于通过每日一次鼻内给药来控制过敏性鼻炎的症状。本文回顾了三项临床报告的结果，这些结果表明，每日一次给予BDP-ds在减轻季节性过敏性鼻炎的鼻部症状方面比安慰剂更有效，且与每日两次给予常规强度的二丙酸倍氯米松效果相同。在开始治疗的2天内即可见到症状改善，并在随后的4周内得以维持。BDP-ds被发现与安慰剂一样安全且耐受性良好。不良反应一般较轻，包括头痛、鼻腔烧灼感/刺激感、鼻出血、咳嗽和咽炎。BDP-ds对6岁的儿童是安全的，其每日一次的给药方案可能会提高患者的依从性。
